These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10969062)

  • 1. Surveillance studies: how can they help the management of infection?
    Masterton RG
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():53-58. PubMed ID: 10969062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance studies: how can they help the management of infection?
    Masterton RG
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():53-8. PubMed ID: 11065148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.
    Jones RN
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():1-8. PubMed ID: 11065144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study.
    Turner PJ
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):273-9. PubMed ID: 16360551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving concepts of pharmaceutical company-sponsored surveillance studies.
    Koeth LM; Miller LA
    Clin Infect Dis; 2005 Aug; 41 Suppl 4():S279-82. PubMed ID: 16032566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility.
    Jones RN
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():1-8. PubMed ID: 10969057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Priorities for antibiotic resistance surveillance in Europe.
    Fluit AC; van der Bruggen JT; Aarestrup FM; Verhoef J; Jansen WT
    Clin Microbiol Infect; 2006 May; 12(5):410-7. PubMed ID: 16643516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preface.
    Reeves D; Wilcox M
    J Antimicrob Chemother; 2000 Aug; 46 Suppl B():III. PubMed ID: 10969063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
    Turner PJ
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States (2004).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):249-57. PubMed ID: 16466890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Alexander Project: the benefits from a decade of surveillance.
    Felmingham D; White AR; Jacobs MR; Appelbaum PC; Poupard J; Miller LA; Grüneberg RN
    J Antimicrob Chemother; 2005 Oct; 56 Suppl 2():ii3-ii21. PubMed ID: 16282278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
    Pfaller MA; Jones RN
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: comparison of antibiotic susceptibilities between countries and centre types. MYSTIC Study Group (European centres only).
    Goossens H
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():39-52. PubMed ID: 11065147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.